Project Grant R16GM159700
Award Date 8/6/25
Completion Date 7/31/29
Dollars Obligated $149K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Puerto Rico
Similar Awards
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This Project Grant award of $543,221.00 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) is supporting research at the Albert Einstein College of Medicine to better understand the cellular and molecular mechanisms driving lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: 1) Define the critical de-differentiated cell states involved in BLBC progression and explore strategies to target these cells for cancer...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- The National Cancer Institute awarded a $134,274 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Tufts University School of Medicine in Boston, MA. The goal of this 3.5-year project, starting December 1, 2024 and ending June 30, 2028, is to investigate the role of the TRPV1 ion channel in driving increased sensory nerve innervation within triple-negative breast cancer (TNBC) tumors. The research aims to uncover the mechanism by which TNBC cells stimulate...
- This $170,127 federal Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training program) is supporting a study at Texas Southern University to investigate the immunoglobulin (Ig) repertoire of tumor-infiltrating B cells in a metastatic HER2-positive breast cancer mouse model. The goal is to identify distinct "public" Igs produced by these B cells that may possess anti-metastatic function. The comprehensive study...
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- The National Cancer Institute (NCI) awarded a 5-year, $676,584 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center (MD Anderson). The grant aims to investigate the genomic evolution and tumor microenvironment dynamics that drive metastatic progression in triple-negative breast cancer (TNBC). Specifically, the project will leverage a postmortem tissue collection program and advanced single-cell genomics techniques to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $395,356 to Georgetown University to conduct research on the mechanisms and pathways of glucocorticoid receptor (GR) signaling in triple negative breast cancer (TNBC) progression. The project aims to examine how communication between "enabler" and "responder" cells in TNBC enhances the GR response, leading to increased invasion and metastasis. Specifically, the...